Lilly reports full Q4 2024 financial results and provides 2025 guidance
1. Q4 2024 revenue surged 45% to $13.53 billion, fueled by Mounjaro, Zepbound growth. 2. Non-incretin revenue rose 20% year-over-year, indicating strong product performance.
StockNews.AI
194 days
FAQ
Why Very Bullish?
The significant revenue increase reflects strong demand, positively impacting LLY's market position, akin to past strong earnings growth indicators.
How important is it?
The article highlights critical revenue growth drivers for LLY, influencing investor sentiment and potential future stock performance significantly.
Why Long Term?
Sustained product growth suggests ongoing revenue momentum, likely boosting LLY's stock value over time, similar to historical performance during successful product launches.